Rallybio (RLYB) Osake Kurssi

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. The company is headquartered in New Haven, Connecticut and currently employs 44 full-time employees. The company went IPO on 2021-07-29. The firm is engaged in identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. The company offers a program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare hematological disease that impacts fetuses and newborns. Its pipeline includes RLYB212, RLYB116, RLYB114, RLYB331 and ENPP1 Program. RLYB212 is a subcutaneously administered human monoclonal anti-HPA-1a antibody candidate for the prevention of HPA-1a maternal alloimmunization and the occurrence of FNAIT. Its advanced product candidate, RLYB116, is an inhibitor of complement component 5 (C5) used to treat complement dysregulation, including paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG) and others. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule designed for the treatment of complement-mediated ophthalmic diseases.